NASDAQ:SLXN Silexion Therapeutics Q2 2026 Earnings Results & Report $0.17 -0.01 (-3.41%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more. Silexion Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 15, 2026. The company reported EPS of -$5.17 versus the -$21.20 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 15, 2026TimeBefore Market Opens Silexion Therapeutics EPS ResultsActual EPS-$5.17Consensus EPS -$21.20Beat/MissBeat by +$16.03One Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersSilexion Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSilexion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Silexion Therapeutics Q2 2026 Earnings FAQ Did Silexion Therapeutics beat earnings estimates for Q2 2026? Silexion Therapeutics (NASDAQ:SLXN) reported earnings of -$5.17 per share for Q2 2026, beating the consensus estimate of -$21.20. The report was announced on Saturday, August 15, 2026. When is Silexion Therapeutics' next earnings date? Silexion Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Silexion Therapeutics on the company's earnings history page. Silexion Therapeutics Earnings HeadlinesSilexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short InterestOctober 11 at 9:41 AM | americanbankingnews.comSilexion Therapeutics Corp Ord Stock Short Interest Rises to 91.58%October 10, 2026 | quiverquant.comQDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 14 at 1:00 AM | Porter & Company (Ad)Silexion Therapeutics consensus price target decreased by 91.67% to $5.10October 1, 2026 | msn.comSilexion Therapeutics begins phase 2/3 SIL204 trial with first patient dosed in pancreatic cancerSeptember 30, 2026 | msn.comSilexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic CancerSeptember 30, 2026 | rttnews.comSee More Silexion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email. Email Address About Silexion TherapeuticsSilexion Therapeutics (NASDAQ:SLXN) Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat. Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment. The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs. Silexion’s work remains focused on advancing its KRAS-targeted platform toward additional clinical studies and potential treatments for patients with difficult-to-treat solid tumors.View Silexion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
